iSpecimen Inc. Material Event - What Happened

This report explains the latest news from iSpecimen Inc. in plain English, so you can understand the situation without needing a finance degree.

1. What happened?

iSpecimen Inc. runs an online marketplace connecting researchers with human biospecimens, such as blood and tissue, from healthcare providers. Nasdaq recently notified the company that it no longer meets the minimum financial requirements to stay listed on the stock exchange.

2. When did it happen?

The company received this formal notice from Nasdaq on May 29, 2026.

3. Why did it happen?

To stay on the Nasdaq Capital Market, companies must maintain at least $2.5 million in "stockholders’ equity"—the value left over for owners if all assets were sold and debts paid. In its quarterly report ending March 31, 2026, iSpecimen reported only $814,038 in equity. Because they fell below the $2.5 million threshold and do not meet alternative standards—such as a $35 million market value or $500,000 in annual profit—they are officially out of compliance.

4. Why does this matter?

This is a "yellow flag" for the company. It does not trigger immediate removal, but it puts the company on a strict timeline. If they cannot show a plan to restore their equity to $2.5 million, they risk being kicked off the Nasdaq. Delisting would move the stock to "over-the-counter" (OTC) markets. These markets usually have lower trading volume and wider price gaps, making it harder for you to buy or sell shares.

5. Who is affected?

• Investors: Shareholders should expect price swings. A deficiency notice often signals financial trouble, which can push the stock price down.
• Customers: iSpecimen helps researchers get specimens. While operations continue, financial uncertainty might cause research partners or hospitals to worry about the company’s long-term stability.
• Employees: Management is now under pressure to fix the balance sheet. This often leads to aggressive cost-cutting or restructuring, which can affect daily operations and staff morale.

6. What happens next?

iSpecimen has 45 days from the May 29 notice to submit a plan to Nasdaq. If Nasdaq accepts the plan, they may grant an extension of up to 180 days to regain compliance. If the plan is rejected, or if the company fails to meet the goals, they will receive a delisting notice. At that point, the company can request a hearing to appeal the decision.

7. What should investors/traders know?

This is a high-stakes situation. To stay listed, the company must increase its equity, which usually means generating more profit or selling new shares. If they sell new shares, they will issue more stock, which reduces your ownership percentage.

How to track this:

• Watch for the Plan: The company is currently working on a compliance plan. They haven't shared specific details on their strategy yet, so keep an eye on their upcoming SEC filings.
• Monitor the Timeline: We are currently within the 45-day window to submit that plan. Any press release regarding a "compliance plan" or "extension" is the most important signal to watch for right now.
• Assess the Risk: If you are holding shares, consider whether you are comfortable with the volatility that comes with a company fighting to stay on a major exchange.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.